Oncorus, Inc. (NASDAQ:ONCR – Get Rating) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 852,400 shares, an increase of 20.7% from the October 31st total of 706,200 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is presently 11.1 days.
Institutional Investors Weigh In On Oncorus
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 23.9% during the 2nd quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after purchasing an additional 30,668 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of Oncorus by 28.9% in the 2nd quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock worth $103,000 after purchasing an additional 18,220 shares during the period. 65.89% of the stock is owned by institutional investors.
Get Oncorus alerts:Wall Street Analysts Forecast Growth
ONCR has been the topic of several research reports. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Wednesday. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday.
Oncorus Price Performance
Shares of Oncorus stock opened at $0.46 on Friday. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.24. The firm's 50 day moving average is $0.69 and its 200 day moving average is $1.11. Oncorus has a 1 year low of $0.41 and a 1 year high of $6.08.About Oncorus
(Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Featured Articles
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.